肾细胞癌的多学科治疗(MDT)前景。

IF 2.6 4区医学 Q2 UROLOGY & NEPHROLOGY Therapeutic Advances in Urology Pub Date : 2023-01-01 DOI:10.1177/17562872231182216

Jeanny B Aragon-Ching, Robert Uzzo

{"title":"肾细胞癌的多学科治疗(MDT)前景。","authors":"Jeanny B Aragon-Ching, Robert Uzzo","doi":"10.1177/17562872231182216","DOIUrl":null,"url":null,"abstract":"able to achieve complete metastasectomy. 14 Metastasectomy can be achieved either with surgery or radiation. The use of stereotactic ablative radiation therapy (SABR) for oligometastatic renal cell carcinoma (ORCA) was evaluated in a meta-analysis of 28 studies, 15 which included 1602 mutually exclusive patients involving 3892 lesions with the potential benefit of effective delivery in lieu of systemic therapy, 16 potential delay of subsequent line of systemic treatment in true oligoprogressive disease or perhaps in combination with systemic therapy. The feasibility of a combination approach","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/81/10.1177_17562872231182216.PMC10286529.pdf","citationCount":"0","resultStr":"{\"title\":\"Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma.\",\"authors\":\"Jeanny B Aragon-Ching, Robert Uzzo\",\"doi\":\"10.1177/17562872231182216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"able to achieve complete metastasectomy. 14 Metastasectomy can be achieved either with surgery or radiation. The use of stereotactic ablative radiation therapy (SABR) for oligometastatic renal cell carcinoma (ORCA) was evaluated in a meta-analysis of 28 studies, 15 which included 1602 mutually exclusive patients involving 3892 lesions with the potential benefit of effective delivery in lieu of systemic therapy, 16 potential delay of subsequent line of systemic treatment in true oligoprogressive disease or perhaps in combination with systemic therapy. The feasibility of a combination approach\",\"PeriodicalId\":23010,\"journal\":{\"name\":\"Therapeutic Advances in Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/81/10.1177_17562872231182216.PMC10286529.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562872231182216\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562872231182216","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma.

able to achieve complete metastasectomy. 14 Metastasectomy can be achieved either with surgery or radiation. The use of stereotactic ablative radiation therapy (SABR) for oligometastatic renal cell carcinoma (ORCA) was evaluated in a meta-analysis of 28 studies, 15 which included 1602 mutually exclusive patients involving 3892 lesions with the potential benefit of effective delivery in lieu of systemic therapy, 16 potential delay of subsequent line of systemic treatment in true oligoprogressive disease or perhaps in combination with systemic therapy. The feasibility of a combination approach

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Therapeutic Advances in Urology Medicine-Urology

CiteScore

3.70

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： Therapeutic Advances in Urology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of urology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in urology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest across all areas of urology, including treatment of urological disorders, with a focus on emerging pharmacological therapies.